CTOs on the Move

Molecular Assemblies

www.molecularassemblies.com

 
At Molecular Assemblies, we are enabling the next era in biotechnology through a completely new approach to DNA synthesis utilizing natural processes. We are developing a platform-independent, scalable DNA synthesis technology designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Josh R.
Director, IT & Cybersecurity Profile

Funding

Molecular Assemblies raised $12.2M on 10/01/2019
Molecular Assemblies raised $11.8M on 04/15/2021
Molecular Assemblies raised $10M on 11/04/2021

Similar Companies

Zevra Therapeutics

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients lives.

St. Patricks Hospital

St. Patricks Hospital is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jasper Clinical Research and Development

Jasper Clinical Research and Development is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ArcherDX

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.

Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. We currently have development pipelines in the fields of dermatology, ophthalmology, orthopedics, and stem cell therapy that highlight the capabilities of our novel drug products.